Trials / Completed
CompletedNCT00637195
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 20 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine co-administered with GlaxoSmithKline Biologicals' HPV vaccine GSK580299 in healthy female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) | Intramuscular administration, 3 doses. |
| BIOLOGICAL | Engerix™ | Intramuscular administration, 4 doses. |
Timeline
- Start date
- 2008-03-11
- Primary completion
- 2008-06-20
- Completion
- 2009-06-18
- First posted
- 2008-03-17
- Last updated
- 2020-01-03
- Results posted
- 2009-12-18
Locations
2 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00637195. Inclusion in this directory is not an endorsement.